Statements (73)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
legislation
|
| gptkbp:aimsTo |
reform patent laws
|
| gptkbp:criticism |
potential impact on drug prices
|
| gptkbp:designedBy |
gptkb:Chuck_Grassley
gptkb:Orrin_Hatch |
| gptkbp:discusses |
Congressional hearings
|
| gptkbp:hasImpactOn |
innovation in drug development
competition in the pharmaceutical market |
| https://www.w3.org/2000/01/rdf-schema#label |
Grassley–Hatch Bill
|
| gptkbp:impact |
pharmaceuticals
biologics |
| gptkbp:includes |
provisions for litigation reforms
provisions for patent term adjustments provisions for patent transparency |
| gptkbp:introduced |
gptkb:United_States_Senate
|
| gptkbp:isActiveIn |
academic studies
legal journals |
| gptkbp:isAttendedBy |
Senate
legal experts economic researchers |
| gptkbp:isCitedIn |
gptkb:Senate_Judiciary_Committee
public forums Senate_floor_discussions |
| gptkbp:isConsidered |
lawmakers
healthcare_committees |
| gptkbp:isCriticizedFor |
legal scholars
consumer advocacy groups complexity of provisions |
| gptkbp:isDiscussedIn |
media outlets
conferences legislative sessions policy forums policy debates. |
| gptkbp:isEvaluatedBy |
think tanks
policy analysts public health experts |
| gptkbp:isExaminedBy |
regulatory agencies
|
| gptkbp:isLinkedTo |
biotechnology industry
drug accessibility issues drug pricing debates healthcare_costs |
| gptkbp:isOrganizedBy |
some state governments
some economists some political groups some healthcare professionals some patient groups |
| gptkbp:isPartOf |
legislative history
health policy initiatives ongoing legislative efforts national policy debates healthcare_policy_discussions healthcare_reform_discussions |
| gptkbp:isProminentIn |
solution to patent issues
|
| gptkbp:isPromotedBy |
advocacy organizations
lobbying groups healthcare_advocates |
| gptkbp:isRelatedTo |
Affordable Care Act
intellectual property law |
| gptkbp:isReviewedBy |
gptkb:Congressional_Budget_Office
health policy experts |
| gptkbp:isSubjectTo |
public opinion
|
| gptkbp:isSupportedBy |
some business groups
some lawmakers some pharmaceutical companies some healthcare organizations some patient advocacy groups |
| gptkbp:opposedBy |
generic drug manufacturers
|
| gptkbp:partOf |
broader patent legislation
|
| gptkbp:relatedTo |
patent reform
|
| gptkbp:status |
proposed
|
| gptkbp:supportedBy |
pharmaceutical industry
|
| gptkbp:wasAffecting |
114th Congress
|
| gptkbp:yearEstablished |
2015
|